

Renal Anemia Chronic Kidney Disease

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Trial Status
Completed

Trial Runs In
7 Countries

Trial Identifier
NCT03552393 2016-004779-39
NH19708

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03552393 2016-004779-39 NH19708
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 3 Months & ≤ 17 Years

Healthy Volunteers
No